Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.45 |
| ▸ | TUBB | P07437 | 2/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.45 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570275 | 1.00 | TUBB1 (0.52) | TUBB1BACE1GAATDP1MAPT | |
| SCHEMBL6933180 | 0.88 | TUBB1 (0.67) | TUBB1GAATDP1MAPTAKR1C3 | |
| SCHEMBL6933178 | 0.88 | TUBB1 (0.67) | TUBB1GAATDP1MAPTAKR1C3 | |
| SCHEMBL16858596 | 0.86 | BACE1 (0.52) | TUBB1BACE1GAATDP1MAPT | |
| SCHEMBL16858595 | 0.86 | BACE1 (0.52) | TUBB1BACE1GAATDP1MAPT | |
| SCHEMBL20500034 | 0.85 | GAA (0.68) | TUBB1GAATDP1MAPTAKR1C3 | |
| SCHEMBL10497247 | 0.85 | GAA (0.68) | TUBB1GAATDP1MAPTAKR1C3 | |
| SCHEMBL10497242 | 0.85 | GAA (0.68) | TUBB1GAATDP1MAPTAKR1C3 | |
| SCHEMBL2085722 | 0.83 | MAPT (0.69) | BACE1GAATDP1MAPTKDM4E | |
| SCHEMBL28944476 | 0.83 | GAA (0.51) | TUBB1GAATDP1MAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| EP-2885286-B1 | 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| EP-2885286-B1 | 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| WO-2015102929-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-07-09 | — | — | WO | disclosed |
| US-20150183802-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| EP-2885286-A1 | 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026997-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183802-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, STS | TUBB1 762/4885BACE1 3676/4885GAA 1907/4885 |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BRD4, BET1, BRDT | TUBB1 242/4885BACE1 496/4885GAA 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.